Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
6.58
-0.12 (-1.79%)
Aug 1, 2025, 4:00 PM - Market closed
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change (1Y)
-58
Growth (1Y)
-65.91%
Revenue / Employee
$39,500
Profits / Employee
-$2,651,000
Market Cap
10.52M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 30 | -58 | -65.91% |
Dec 31, 2023 | 88 | 30 | 51.72% |
Dec 31, 2022 | 58 | 5 | 9.43% |
Dec 31, 2021 | 53 | 15 | 39.47% |
Dec 31, 2020 | 38 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LYRA News
- 5 weeks ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 2 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 2 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 3 months ago - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire